EyeGene

At a glance

EyeGene filed 47 disclosures in the last 12 months, including 19 insider and 3 5% holder. The most recent key filing was on Aug 3.

Revenue for 2025 was ₩3.6B, up 6.3% on 2024. It made an operating loss of ₩9.9B. Debt was 25% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.6B and operating loss of ₩7.5B.

The 2025 annual report lists 49 employees with an average tenure of 4.8 years and average pay of ₩58.6M. Its 5 directors and auditors were paid ₩106M each on average. It paid no cash dividend for 2025. 주식회사 한국비엠아이 and related parties held 28.40% at year end.

From the 2025 annual report

Staff: 49 (28 men, 21 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩2.9B. Directors and auditors: 5, paid ₩532M in total.

No cash dividend was paid for 2025.

Largest shareholder

주식회사 한국비엠아이 holds 23.16%; with 7 related parties the group holds 28.40% of common shares at year end (from 27.90% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary